Johns Hopkins Medicine Johns Hopkins Logo
make a gift
hopkins urology on you tube  twitter urology department at hopkins   facebook urology department at hopkins  blog urology department at hopkins  
Georges J Netto, MD George Netto, M.D.

Director of Surgical Pathology Molecular Diagnostics
Professor of Pathology, Urology and Oncology

Johns Hopkins University School of Medicine

George Jabboure Netto, M.D., is a Professor in the Department of Pathology, Urology and Oncology and a Staff Member of the Sidney Kimmel Comprehensive Cancer Centre at Johns Hopkins Medical Institution. He is the Director of Surgical Pathology Molecular Diagnostics and the Associate Editor for Basic and Translational Section of the gold journal "Urology" and the Associate Editor of Urology Case Reports.

Dr. Netto has a strong record as clinician scientist of special expertise in the areas of genitourinary pathology and molecular pathology.  He is best known for his work in translational molecular research in bladder cancer, prostate cancer and renal cancers.

In addition, he has cultivated a strong expertise and reputation in the field of Molecular Diagnostics with special interest in molecular applications to the diagnosis and prognostication of solid tumors. Dr. Netto's scholarly activities have resulted in over two hundred articles publications in peer reviewed medical journals. He is a co-author of four books in urologic pathology and a co-editor of a new textbook in genomic applications in pathology.

  He is an actively sought speaker for national and international lectures in the fields of urologic oncology and molecular diagnostics.


Doctor of Medicine 1979 - 1985 Damascus University
Damascus, Syria
Residency in Anatomic & Clinical Pathology
1987 - 1991 Department of Pathology
Baylor University Medical Center
Chief Resident 1991 - 1992 Department of Pathology
Baylor University Medical Center
Surgical Pathology Fellowship 1992 - 1993 Lauren V. Ackerman Laboratory
Barnes Hospital, Washington University
St.Louis, Missouri
Urologic Pathology Fellowship 993 - 1994 Memorial Sloan-Kettering Cancer Center
New York, New York


  • Texas Medical License 1991

  • New York State Medical License 2004

  • American Boards of Anatomic and Clinical Pathology 1992




  1. Prostate Biopsy Interpretation JI Epstein & GJ Netto
    Fourth Edition; Lippincott Williams& Wilkins, Philadelphia, 2007


  1. Immunohistology and Molecular Diagnostics of The Prostate Neoplasms GJ Netto and JI Epstein. Chapter 16 Section I; in Diagnostic Immunohistochemistry. Churchill Livingston Elsevier, Third Edition, Ed. David Dabbs Ed. IN PRESS

  2. Immunohistology and Molecular Diagnostics of The Urinary Bladder Neoplasms GJ Netto and JI Epstein. Chapter 16 Section II; in Diagnostic Immunohistochemistry. Churchill Livingston Elsevier, Third Edition, Ed. David Dabbs Ed. IN PRESS

  3. Immunohistology and Molecular Diagnostics of The Renal Neoplasms GJ Netto and JI Epstein. Chapter 16  Section III; in Diagnostic Immunohistochemistry. Churchill Livingston Elsevier, Third Edition, Ed. David Dabbs Ed. IN PRESS

  4. Immunohistology and Molecular Diagnostics of The Testicular Neoplasms. GJ Netto and JI Epstein. Chapter 16 Section IV; in Diagnostic Immunohistochemistry. Churchill Livingston Elsevier, Third Edition, Ed. David Dabbs Ed. IN PRESS

  5. BENIGN MIMICKERS OF PROSTATE ADENOCARCINOMA ON NEEDLE BIOPSY & TRANSURETHRAL RESECTION: George J. Netto and Jonathan I Epstein Surgical Pathology Clinics, 2008 Volume 1, Issue 1, ISSN: 1875-9181 SAUNDERS

  6. Mesenchymal Tumors of the Prostate Donna E. Hansel MD PhD, George J Netto MD, Elizabeth A. Montgomery MD and Jonathan I. Epstein MD. Surgical Pathology Clinics, 2008 Volume 1, Issue 1, ISSN: 1875-9181 SAUNDERS

  7. Pathology of Liver Transplantation: Complications of Liver Transplantation. GJ Netto. chapter 34; Atlas of Liver Transplantation: Molmenti & Klintmalm; Ed; Elsevier Science 2002.

  8. Pathology of Liver Transplantation: Primary Hepatic Disease. GJ Netto.chapter 35; Atlas of Liver Transplantation: Molmenti & Klintmalm; Ed; Elsevier Science 2002.        
  9. Pathology of Liver Transplantation: Recurrence of Primary Hepatic Diseases in Transplanted Livers. GJ Netto. chapter 36; Atlas of Liver Transplantation: Molmenti & Klintmalm; Ed; Elsevier Science 2002.

  10. Pathology of Liver Transplantation; Grading and staging Systems. GJ Netto . chapter 37; Atlas of Liver Transplantation: Molmenti & Klintmalm; Ed; Elsevier Science 2002.

Selected Peer Reviewed Articles

  1. Sarkis A, Bajorin D, Reuter V, Herr H, Netto G, Zhang Z-F , Schultz P, Cordon-Cardo C and Scher H:  Prognostic Value of p53 Nuclear Overexpression in Patients with Invasive Bladder Cancer Treated with Neoadjuvant MVAC. Journal of Clinical Oncology 1995; 13: 1384-1890.

  2. Scher H, Sarkis A, Reuter V, Cohen D, Netto G, Petrylak D, Lianes P, Fuks Z, Mendelsohn J and Cordon-Cardo C: Changing Pattern of Expression of the Epidermal Growth Factor Receptor and Transforming Growth Factor Alpha in the Progression of Prostatic Neoplasms. Clin. Cancer Res. 1995; 1(5): 545-550
  3. Nord JD, Stolfi RL, Alfieri AA, Netto G, Reuter V, Sternberg SS, Colofiore JR, Koultcher JA and Martin DS:  Apoptosis Induced in Advanced CD8F1- Murine Mammary Tumors by the Combination of PALA, MMPR and 6AN Precedes Tumor Regression and is Preceded by ATP Depletion.  Cancer Chemother Pharmacol.  1997; 40 (5): 376-384.
  4. Hogenauer C, Meyer RL, Netto GJ, Bell D, Little KH, Ferries L, Santa Ana CA, Porter JL, Fordtran JS :  Malabsorption due to cholecystokinin deficiency in a patient with autoimmune polyglandular syndrome type I. N. Engl. J. Med. 2001 ; 344:270-274.

  5. Nemunaitis J, Cunningham C, Tong AW, Post L, Netto G, Paulson AS, Rich D, Blackburn A, Sands B, Gibson B, Randlev B, Freeman S.: Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Ther 2003; (10):341-52.
  6. Islas-Ohlmayer M, Padgett-Thomas A, Saad R, Melkus M, Cravens P. Martin M, Netto G and Garcia JV. Experimental Infection of NOD/SCID Mice Reconstituted with Human CD34+ Cells with Epstein-Barr Virus. J Virol 2004 (78): 13891-13900
  7. Tong A, Nemunaitis J, Su D, Zhang Y, Cunningham C, Senzer N, Netto G, Rich D, Mhashilkar A, Parker K, Coffee K, Ramesh R, Ekmekcioglu S, Grimm EA, van Wart Hood J, Merritt J and Chada S. Intratumoral Injection of INGN 241, a Nonreplicating Adenovector Expressing the Melanoma-Differentiation Associated Gene-7 (mda-7/IL24): Biologic Outcome in Advanced Cancer Patients.
    Molecular Therapy 2005; (1):160-72.
  8. Sanchez S, Holmes H, Katabi N, Newman J, Domiatti-Saad R, Stone M and Netto GJ.  Composite Lymphocyte Rich Hodgkin Lymphoma and Peripheral T Cell Lymphoma Associated wih Epstein-Barr Virus. Case Report and Literature Review. Arch Pathol Lab Med 2006:130:107-112.
  9. G J Netto, DL Watkins, J W Williams, T Colby, G dePetris, F Sharkey, C Corless, D Lewin , L Petrovic, S Sharma, G Kanel , N Theise, A B West, A Koehler, N Jhala, J Lefkowitch, J Lezzoni, Linda Jennings, GW Tillery, G Klintmalm and The Hepatitis C 3 Trial Group. : Interobserver Agreement in Hepatitis C Grading and Staging and Banff Grading Schema for Acute Cellular Rejection: The “Hepatitis C 3” Multi-institutional Trial Experience. Arch Pathol Lab Med 2006:130:1157-1162
  10. Netto GJ, Altrabulsi  B, Katabi N, Martin P, Burt K, Levy M, Sanchez E, Watkins DL, Jennings L, Klintmalm G and Goldstein R: Radio Frequency Ablation of Hepatocellular Carcinoma Prior to Liver Transplantation: A Histologic and TUNEL Study. Liver International 2006: 26(6): 746-751
  11. Ueno T, Barri YM, Netto GJ, Martin A, Onaca N, Sanchez EQ, Chinnakotla S, Randall HB, Dawson S, Levy MF, Goldstein RM, Klintmalm GB. Liver and kidney transplantation for polycystic liver and kidney-renal function and outcome. Transplantation. 2006: 82:501-5077.
  12. Netto GJ, Epstein JI: Widespread High Grade Prostatic Intraepithelial Neoplasia on Prostatic Needle Biopsy: A Significant Likelihood of Subsequently Diagnosed Adenocarcinoma. Am J Surg Pathol 2006: 30(9):1184-1188
  13. E Kuhn, J De Anda, S Manoni, G Netto and J Rosai: Renal Cell Carcinoma Associated with Prominent Angioleiomyoma-Like Proliferation: Report of Five cases and review of The Literature. Am J Surg Pathol 2006: 30(11): 1372-1361
  14. Hansel DE, DeMarzo AM, Platz EA, Jadallah S , Hicks J, Epstein1JI, Partin AW, and Netto GJ: Early Prostate Cancer Antigen (EPCA) Expression in Predicting Presence of Prostate Cancer among Men with Histologically Negative Biopsies. J Urol  2007: 177(5): 1736-1740
  15. Owens C, Epstein JI and Netto GJ: Distinguishing Prostatic From Colorectal Adenocarcinoma on Biopsy Samples: The Role of Morphology and Immunohistochemistry. Arch Pathol Lab Med 2007:131(4);599-603
  16. Gilliland GD, Gilliland G, Fincher T, Harrington J, Gilliland JM, Netto G and Burt K. Timing of return to normal activities after orbital floor fracture repair. Plast Reconstr Surg. 2007;120:245-251.
  17. Paulson KE, Rieger-Christ K, McDevitt MA, Kuperwasser C, Kim J, Unanue VE, Zhang X, Hu M, Ruthazer R, Berasi SP, Huang CY, Giri D, Kaufman S, Dugan JM, Blum J, Netto G, Wazer DE, Summerhayes IC, and Yee AS. Alterations of the HBP1 Transcriptional Repressor Are Associated with Invasive Breast Cancer. Cancer Res. 2007;67:6136-45.
  18. Klintmalm GB, Washburn WK, Rudich SM, Heffron TG, Teperman LW, Fasola C, Eckhoff DE, Netto GJ, Katz E. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl. 2007;13(11):1521-31.
  19. Grosso GF, Kelleher CC, Timothy J. HarrisTJ, Maris CH, Hipkiss EL, DeMarzo A, Anders R,  Netto G, Getnet D, Bruno TB, Goldberg MV, Pardoll DM and Drake CG. Expression of LAG-3 on CD8 T cells regulates their accumulation and effector function in murine self and tumor tolerance systems. J Clin Investigation 2007: 117(11):3383-92
  20. Osunkoya AO, Netto GJ, Epstein JI: Colorectal adenocarcinoma involving the prostate: report of 9 cases. Hum Pathol 2007; 38(12):1836-41
  21. Lane Z, Epstein JI, Ayub S and Netto GJ : Prostatic Adenocarcinoma In Colorectal Biopsy: Clinical And Pathologic Features. Hum Pathol 2008; 39(4):543-9.
  22. Osunkoya AO, Hansel DE, Sun X, Netto GJ, Epstein JI. Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases. Am J Surg Pathol. 2008 Mar;32(3):461-7.
  23. Sireci AN, Rodriguez  R, Swierczynski  SL, Netto GJ and Argani, P:  Fat-Predominant Mixed Epithelial Stromal Tumor (MEST):  Report of a Unique Case Mimicking Angiomyolipoma.  Int J Surg Pathol  2008;16(1):73-7.
  24. Nagpal JK, Dasgupta S, Jadallah S, Chae YK, Ratovitski EA, Toubaji A, Netto GJ, Eagle T, Nissan A, Sidransky D, Trink B. Profiling the expression pattern of GPI transamidase complex subunits in human cancer. Mod Pathol. 2008 (8):979-91.
  25. Argani P, Netto GJ, Parwani AV.Papillary renal cell carcinoma with low-grade spindle cell foci: a mimic of mucinous tubular and spindle cell carcinoma.Am J Surg Pathol. 2008(9):1353-9
  26. Goodwin AC, Jadallah S, Toubaji A, Lecksell K, Hicks J,Kowalski J, Bova GS, 3, De Marzo AM, Netto GJ, and Casero RA Jr: Increased Spermine Oxidase Expression in Human Prostate Cancer and Prostatic Intraepithelial Neoplasia Tissues. Prostate 2008 (7):766-72
  27. Netto GJ, Nakai Y, Nakayama M, Jadallah S, Toubaji A, Nonomura N, Albadine R , Hicks J, Epstein JI, Yegnasubramanian S, Nelson WG, and De Marzo AM: Global DNA Hypomethylation in Intratubular Germ Cell Neoplasia and Seminoma, but Not in Non-Seminomatous Male Germ Cell Tumors. Modern Pathol 2008; 21(11):1337-44.
  28. Wang W, Tavora F, Sharma R, Eisenberger M and Netto GJ. PSMA Expression in Schwannoma: A Potential Clinical Mimicker of Metastatic Prostate Carcinoma. Urol Oncology (In Press)
  29. Cheung WL, Albadine R, Chan T, R. Sharma R and Netto GJ: Phosphorylated H2AX in Non-Invasive Low Grade Urothelial Carcinoma of Urinary Bladder: Correlation with Tumor Recurrence. J Urol  (In Press)
  30. R Albadine, W Wang, NA Brownlee, A Toubaji, A Billis, JI Epstein, P Argani, AJ Garvin, Couzi, R, E Schaeffer,CP Pavlovich, GJ Netto: Topoisomerase IIA Status in Renal Medullary Carcinoma: Immunoexpression and Gene Copy Alterations of a Potential Target of Therapy.  J Urol (In Press)
  31. Klock C, Gomes R, João M, Netto G. Prostate Melanosis Associated With Acinar Adenocarcinoma. Int J Surg Pathol. (In Press)
  32. Tamara L. Lotan, Antoun Toubaji, Roula Albadine, Mathieu Latour, Mehsati Herawi, Alan K. Meeker, Angelo M. DeMarzo, Elizabeth A. Platz, Jonathan I. Epstein, and George J. Netto TMPRSS2-ERG Gene Fusions are Infrequent in Prostatic Ductal Adenocarcinomas. Modern Pathol (In Press)
  33. K Fujita, CP Pavlovich, G Netto, Y Konishi, WB Isaacs, S Ali, A De Marzo and A Meeker: Specific detection of prostate cancer cells in urine by multiplex immunofluorescence cytology. Hum Pathol (In Press)
  34. Margulis V, Lotan Y, Karakiewicz PI, Fradet Y, Ashfaq R, Capitanio U, MontorsiF, Bastian PJ, Nielsen ME, Müller SC, Rigaud J, Heukamp LC, Netto G, Lerner SP, Sagalowsky AI, Shariat SF. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer.J Natl Cancer Inst. 2009 Jan 21;101(2):114-9.


  • College of American Pathology

  • SOCIETIES American Society of Clinical Pathology

  • Association of Molecular Pathology

  • American College of Medical Genetics

  • International Academy of Pathology

  • International Academy of pathology - Arab Division


1982    Henry Strong Denison Award for Medical Research

1987    Sandoz Award for Outstanding Research in Pharmacology

1987    Warfield T. Longcope Prize for Excellence in Clinical Medicine

1987    Alpha Omega Alpha


  1. 1- NIH/NCI Grant: P01 CA077664-06
    Tissue Core A - High Throughput Genetic Analysis of Bladder Cancer.
    Principal Investigator
    Annual Direct Cost:  $50,786 @ 25% effort
    5/31/05 - 11/30/09
    Goal: Establish a comprehensive integrated fresh frozen tissue procurement and histopathology
    database for bladder cancer  as a source of tumor DNA/RNA for  the investigation of high throughput genetic analysis of urothelial carcinoma.

    2- Biomarker Expression in Prostate Cancer TMAs

    Principal Investigator
    Budget Number: M630-640-2078
    Funding Source: Prostate Cancer Foundation 1250 Fourth Street,
    Santa Monica, CA 90401
    Annual Direct Cost: $75,000 @ 4% effort
    02/01/06 - 010/31/07
    Goal: evaluate the role of biomarkers expression in prostate cancer in predicting prognosis and idenifying  potential targets of therapy in a nested case control cohort using Tissue Micro Array analysis.

    3-SMO/PAOh1 Expression in Prostatic Carcinoma

    Funding Source: the Patrick C. Walsh Prostate Cancer Research Fund.
    Annual Direct Cost: $75,000 @ 4% effort
    04/01/06 - 03/31/08

     Goal: Determine the relationship of SMO/PAOh1 expression and stage and grade of prostate cancers using tissue microarrays (TMA). Determine the role of TNF-α in the regulation of SMO/PAOh1 expression in human prostate cancer cells.

    4-Inter-SPORE Prostate Biomarkers Study Centralized Pathology     
    Core (IPBS-CPC)

    Funding Source: NIH/NCI
    Annual Direct Cost: $193,327 @ 6% effort
    04/01/06 - 03/31/08
    Goal:The Inter-SPORE Prostate Biomarkers Study (IPBS) and National Biospecimen Network (NBN) Pilot is a multi-SPORE effort among 11 institutions to rigorously evaluate 5 promising biomarkers for prostate cancer prognosis in men treated by prostatectomy or radiation.  The overall goal is to determine the ability of candidate biomarkers to improve prediction of recurrence beyond that achievable with existing nomograms based on clinico-pathologic factors.

    5- Evaluation of TMPRSS2/ETS fusion genes by FISH in Progression Prostate Carcinoma TMA

    Principal Investigator
    Budget Number: 80017568
    Funding Source: the Patrick C. Walsh Prostate Cancer
    Annual Direct Cost: $75,000 @ 4% effort Budget Period
    04/01/07 - 03/31/08
    Assess the prognostic significance of the newly discovered TMPRSS2/ETS fusion genes using interphase fluorescence in situ hybridization (FISH) technology applied to The Johns Hopkins Brady Urological Institute PSA-Era Case-Control Progression Tissue Microarray Set constructed from radical prostatectomy samples as a nested set from patients enrolled in the study of “The Natural History of Prostate Cancer after Radical Prostatectomy”.

    6- Role of GPI Complex subunits in human bladder cancer

    Funding Source: Flight attendant medical research institute (FAMRI)
    Project Period: 7/1/07-6/30/08
    Budget Period: 7/1/07-6/30/08
    Annual Direct Cost: $100,000 @2% effort
    The overall objective of the study is to establish a causative link between PIG-U, PIG-T and GPAA1 and progression of bladder cancer which may be induced by cigarette smoking and test the effect of proaerolysin as a therapeutic agent.

    7- Identification of Biomarkers for Testicular cancer
    R03- CA128060-01A1
    Funding Source :NCI
    Project Period: 9/24/07-9/23/09
    Budget Period: 9/24/07-9/23/09
    Annual Direct Cost: $50,000 @1% effort
    The overall objective of the study is to assess gene methylation status in seminomatous & non-seminomatous GCT and its potential use in guiding prognosis/therapy

    8- SPORE in Prostate Cancer
    P50 CA58236 (Nelson)                                              
    04/01/08-03/31/13       0.36 calendar
    NIH-NCI                    $134,001        
    Core B – Specimen Core (De Marzo/Netto)
    The major goals of this project are to perform a prospective study of tissue and serum biomarkers for prediction of aggressiveness of prostate cancer. The study is also a pilot for the National Biospecimen Network

    9- Methylation Markers of Bladder Cancer Recurrence
    FAMRI Clinical Innovator Award 2009 (Netto)          
    07/ 01/09-06/30/12      1.2 calender
    Flight Attendant Medical Research Institute               $108.000
    The major goals of this project is to identify gene promotor methylation markers in urine specimens that will help predict and/or detect early bladder cancer recurrence.

    10- The Oncogenic miR-21 Gene Locus in Advanced Prostate Cancer
    Patrick C Walsh Prostate Cancer Foundation(Lupold)
    07/ 01/09-06/30/12                                                     
    $75,000       0.6 calender
    The goals of this project is the evaluation of miR-21 and TMEM49 expression and miR-21 gene locus copy number in advanced prostate cancer and their potential role in cancer progression




  • Address:
    Division of Surgical Pathology
    Weinberg Building Room 2242
    Baltimore, MD 21231 2410
  • Office: (410) 955-5082

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.| Disclaimer
Email: | 600 North Wolfe Street, Baltimore, Maryland 21287